NASDAQ:AIMT - Aimmune Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$27.29 -0.42 (-1.52 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$27.29
Today's Range$27.2150 - $28.11
52-Week Range$24.56 - $42.00
Volume293,524 shs
Average Volume493,213 shs
Market Capitalization$1.62 billion
P/E Ratio-10.46
Dividend YieldN/A
Beta-0.27
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220

Debt

Debt-to-Equity RatioN/A
Current Ratio8.22
Quick Ratio8.22

Price-To-Earnings

Trailing P/E Ratio-10.46
Forward P/E Ratio-7.50
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book7.80

Profitability

EPS (Most Recent Fiscal Year)($2.61)
Net Income$-131,320,000.00
Net MarginsN/A
Return on Equity-69.64%
Return on Assets-62.00%

Miscellaneous

Employees131
Outstanding Shares58,480,000
Market Cap$1.62 billion

Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) issued its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.05. View Aimmune Therapeutics' Earnings History.

When is Aimmune Therapeutics' next earnings date?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 5th 2018. View Earnings Estimates for Aimmune Therapeutics.

What price target have analysts set for AIMT?

9 brokers have issued 12 month price targets for Aimmune Therapeutics' shares. Their predictions range from $30.00 to $80.00. On average, they anticipate Aimmune Therapeutics' share price to reach $52.5567 in the next year. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

What is the consensus analysts' recommendation for Aimmune Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/24/2018)
  • 2. Cantor Fitzgerald analysts commented, "A stock now perhaps better suited for investors than traders. In our view, the investment profile for AIMT stock changed significantly once top-line data from the Phase 3 PALISADE trial were released. Aside from the company’s IPO, maybe, the data release constitutes the most important event in the company’s history, we believe. Although AIMT plans to develop other treatments, because peanut allergy is the most prevalent food allergy, the NPV of additional therapies is probably lower than that of AR101. We suspect, too, that the market may discount a higher pTS for other programs now that POC has been established." (5/9/2018)

Who are some of Aimmune Therapeutics' key competitors?

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 58)
  • Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 51)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 61)
  • Dr. Stephen George Dilly, Special Advisor (Age 58)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Who are Aimmune Therapeutics' major shareholders?

Aimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Xact Kapitalforvaltning AB (0.01%) and Atria Investments LLC (0.01%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

Which institutional investors are buying Aimmune Therapeutics stock?

AIMT stock was bought by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB and Atria Investments LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $27.29.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $1.62 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is http://www.aimmune.com.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]


MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by MarketBeat.com Staff

Featured Article: NASDAQ

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel